Johnson & Johnson

Johnson & Johnson Earnings Recaps

JNJ Health Care 2 recaps
Q1 2026 Apr 14, 2026

Johnson & Johnson delivered a robust Q1 2026 with 6.4% operational sales growth, driven by strong performances across its innovative pharma and MedTech segments, and raised full-year guidance toward $100 billion revenue.

Key takeaways
  • Q1 revenue grew 6.4% annually, with Innovative Medicine up 7.4% and MedTech up 4.6%, reflecting broad-based momentum.
  • Oncology led with 18% growth in DARZALEX and FDA approvals for TECVAYLI and CARVYKTI, expanding pipeline impact.
  • Immunology sales surged 64%, driven by TREMFYA, and FDA approval of ICOTYDE positions the company for significant market share in immunology.
  • MedTech’s cardiovascular segment showed strength in ablation and circulatory recovery, with innovative platforms like VARIPULSE and OMNYPULSE gaining traction.
  • The company remains on track for $100 billion in 2026 revenue, with confidence in sustained double-digit growth through 2027.
Full recap
Q3 2025 Oct 14, 2025

Johnson & Johnson's Q3 2025 performance demonstrates strong operational growth across its business sectors, with a 5.4% increase in sales, underscoring the company's successful innovation strategy and market resilience.

Key takeaways
  • Innovative Medicine achieved operational sales growth of 5.3%, propelled by robust performance from 11 key brands, including a 40% surge in TREMFYA sales.
  • MedTech saw even higher operational growth of 5.6%, fueled by improvements in all subdivisions and the planned separation of the Orthopaedics business to enhance focus on high-growth areas.
  • Oncology sales rose nearly 20%, driven by market-leading products like DARZALEX and CARVICTI, which now stands as the most successful CAR T therapy launch globally.
  • The FDA approval of Inlexo for bladder cancer treatment showcases J&J's innovative capabilities and solidifies potential $5 billion annual peak sales for the product.
  • J&J is expanding its immunology portfolio, with a strong forecast for TREMFYA, which has gained significant market share within its first year of launch.
Full recap